Drug Development Pharma - July 16, 2015
Priority Review for Janssen Drug
The US Food and Drug Administration (FDA) has approved under priority review Janssen Pharmaceuticals’ New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Priority review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions. In a long-term maintenance trial, 93 percent of patients […]
